TGTX (TG Therapeutics) FCF Margin %: -8.76% (As of Mar. 2026)


TGTX TG Therapeutics Inc TGTX
82 GF Score
Price $54.90
GF Value $58.08
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is TG Therapeutics FCF Margin %?

TG Therapeutics TGTX +1.84% 82 FCF Margin % is -8.76% as of Mar. 2026. GuruFocus rates TGTX with a GF Score™ of 82/100 and a GF Value™ of $58.08 (Fairly Valued). The stock has 7 warning signs investors should review. Among 959 Biotechnology companies, TG Therapeutics ranks better than 73.62% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. TG Therapeutics's Free Cash Flow for the three months ended in Mar. 2026 was $-17.9 Mil. TG Therapeutics's Revenue for the three months ended in Mar. 2026 was $204.9 Mil. Therefore, TG Therapeutics's FCF Margin % for the quarter that ended in Mar. 2026 was -8.76%.

As of today, TG Therapeutics's current FCF Yield % is -0.17%.

The historical rank and industry rank for TG Therapeutics's FCF Margin % or its related term are showing as below:

TGTX' s FCF Margin % Range Over the Past 10 Years
Min: -141357.89   Med: -23535.13   Max: -2.03
Current: -2.03

During the past 13 years, the highest FCF Margin % of TG Therapeutics was -2.03%. The lowest was -141357.89%. And the median was -23535.13%.

TGTX's FCF Margin % is ranked better than
73.62% of 959 companies
in the Biotechnology industry
Industry Median: -84.65 vs TGTX: -2.03

TG Therapeutics FCF Margin % Related Terms

TG Therapeutics FCF Margin % Historical Data

* Premium members only.

The historical data trend for TG Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TG Therapeutics FCF Margin % Chart

TG Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4,425.70 -6,326.18 -13.44 -12.33 -4.05

TG Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -23.78 5.24 -14.37 10.17 -8.76

TGTX vs SRRK, COGT, RYTM: FCF Margin % Comparison

For the Biotechnology subindustry, TG Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TG Therapeutics FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TG Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where TG Therapeutics's FCF Margin % falls into.


TGTX
82GF Score
TG Therapeutics Inc TGTX
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TG Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

TG Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-24.986/616.287
=-4.05 %

TG Therapeutics's FCF Margin for the quarter that ended in Mar. 2026 is calculated as

FCF Margin=Free Cash Flow (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-17.945/204.918
=-8.76 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of -8.76% mean?
TG Therapeutics (TGTX) has a FCF Margin % of -8.76% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on TG Therapeutics and its competitors. According to the industry distribution chart, TG Therapeutics ranks #253 out of 959 companies in the Biotechnology industry, placing it in the top 26.4%.
Is TG Therapeutics' FCF Margin % too high?
TG Therapeutics' current FCF Margin % is -8.76%. Based on the distribution chart, TG Therapeutics ranks #253 out of 959 companies in the Biotechnology industry, which is above the industry midpoint. Overall, TG Therapeutics has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does TG Therapeutics' FCF Margin % compare to SRRK and COGT?
According to the Biotechnology industry distribution chart, TG Therapeutics ranks #253 out of 959 companies for FCF Margin %. This puts TG Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on TG Therapeutics and its competitors. TG Therapeutics's current FCF Margin % is -8.76%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TG Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, TG Therapeutics (TGTX) is currently considered Fairly Valued. The stock's GF Value™ is $58.08, compared to a current price of $54.90 — trading 5.5% below its estimated fair value. The current FCF Margin % is -8.76%. TG Therapeutics' overall GF Score™ is 82/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For TG Therapeutics (TGTX), the current FCF Margin % is -8.76% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is TG Therapeutics (TGTX) Overvalued in 2026?

Based on GuruFocus' analysis, TG Therapeutics stock appears to be undervalued. The current stock price of $54.90 is trading 5.5% below its estimated GF Value™ of $58.08. GuruFocus considers TG Therapeutics to be Fairly Valued.

Key valuation signals for TGTX:

  • FCF Margin %: -8.76%
  • GF Value™: $58.08 vs. price of $54.90 (5.5% below fair value)
  • GF Score™: 82/100 with 7 warning signs

No single metric tells the full story. See the TGTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

TG Therapeutics Business Description

Other Exchanges 1TGTX:ItalyNKB2:Germany
Address 3020 Carrington Mill Boulevard, Suite 475, Morrisville, NC, USA, 27560
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.
82GF Score

Get the complete analysis for TGTX

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$54.90
Price
$58.08
GF Value